Neogen Reports Q3 2025 Results: Revenues Fall, Net Losses Widen Amid Goodwill Impairment

Neogen Corporation (NASDAQ: NEOG) - Q3 2025 Financial Review

Neogen Corporation has recently released its quarterly financial results for the period ending February 28, 2025, showing various challenges and highlights in its operations.

Key Points and Statistics:

• Total Revenues: $220.98 million, down from $228.81 million in Q3 2024 (-3.4%).
• Net Loss: $10.96 million, compared to a net loss of $2.02 million in Q3 2024.
• Cost of Revenues: $110.72 million, slightly down from $111.93 million in Q3 2024.
• Gross Profit: $110.27 million, down from $116.88 million in Q3 2024.
• Operating Expenses: $104.85 million, nearly flat compared to $104.86 million in Q3 2024.
• Goodwill Impairment Charge: $461.39 million recorded in the first nine months of FY 2025.
• Cash and Cash Equivalents: $127.7 million as of February 28, 2025.
• Inventory Levels: Net inventories increased to $205.44 million from $189.27 million.
• Average Shares Outstanding: 217.03 million for Q3 2025, resulting in a net loss per share of $(0.05).

Positive Aspects:

• Operational Growth: Despite revenue decreases, there was growth in specific product lines, particularly in food safety diagnostics.
• Cost Control: Operating expenses remained stable, indicating effective cost management.
• Cash Liquidity: Sufficient liquidity with $127.7 million in cash, allowing for continued operational sustainability.

Negative Aspects:

• Declining Revenues: A significant drop in total revenues year-over-year, with a decrease attributed partly to foreign exchange impacts.
• Increased Losses: Substantial increase in net losses driven by goodwill impairment and lower operating income.
• Higher Inventory Levels: Increased inventory levels may indicate potential overstock or challenges in sales execution.
• Goodwill Impairment: The company faced a substantial impairment charge, indicating potential future operating difficulties.

Overall, while Neogen Corporation (NASDAQ: NEOG) is navigating through challenges with fluctuating revenues and increased losses, it maintains a stable position with cash reserves and operational focus on improving specific product lines. Investors should keep a close watch on management's future strategies, particularly in light of recent goodwill impairments and changing market dynamics.